This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Sep;51(9):1583-4.

doi: 10.3109/10428194.2010.508190.

Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma

Kieron Dunleavy¹, Wyndham H Wilson

Affiliations

PMID: 20795788
DOI: 10.3109/10428194.2010.508190

Comment

Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma

Kieron Dunleavy et al. Leuk Lymphoma. 2010 Sep.

. 2010 Sep;51(9):1583-4.

doi: 10.3109/10428194.2010.508190.

Authors

Kieron Dunleavy¹, Wyndham H Wilson

Affiliation

¹ Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

PMID: 20795788
DOI: 10.3109/10428194.2010.508190

No abstract available

PubMed Disclaimer

Comment on

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE, Raphael BG. Amengual JE, et al. Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091. Leuk Lymphoma. 2010. PMID: 20572801 No abstract available.

Similar articles

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Amengual JE, Raphael BG. Amengual JE, et al. Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091. Leuk Lymphoma. 2010. PMID: 20572801 No abstract available.
Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
Zhu WM, Li Y, Yu C, Li N, Li JS. Zhu WM, et al. Inflamm Bowel Dis. 2011 Jul;17(7):E72-3. doi: 10.1002/ibd.21733. Epub 2011 Apr 27. Inflamm Bowel Dis. 2011. PMID: 21538714 No abstract available.
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M. Jiang L, et al. Br J Haematol. 2009 Apr;145(2):173-9. doi: 10.1111/j.1365-2141.2009.07606.x. Epub 2009 Feb 19. Br J Haematol. 2009. PMID: 19236377 Free PMC article.
Alemtuzumab in B-cell chronic lymphocytic leukemia.
Shapira I, Grossbard ML. Shapira I, et al. Clin Lymphoma. 2004 Mar;4(4):228-9. doi: 10.1016/s1526-9655(11)70038-0. Clin Lymphoma. 2004. PMID: 15072614 Review. No abstract available.
Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P, Hillmen P. Moreton P, et al. Semin Oncol. 2003 Aug;30(4):493-501. doi: 10.1016/s0093-7754(03)00253-7. Semin Oncol. 2003. PMID: 12939718 Review.

See all similar articles

Cited by

Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK, Jain S, Barta SK, Tolu S, Estrella B, Sawas A, Lue JK, Francescone MM, Pro B, Amengual JE. Ryu Tiger YK, et al. Leuk Lymphoma. 2024 Jun;65(6):736-745. doi: 10.1080/10428194.2024.2329996. Epub 2024 Mar 22. Leuk Lymphoma. 2024. PMID: 38517235 Free PMC article. Clinical Trial.
Stability of alemtuzumab solutions at room temperature.
Goldspiel JT, Goldspiel BR, Grimes GJ, Yuan P, Potti G. Goldspiel JT, et al. Am J Health Syst Pharm. 2013 Mar 1;70(5):439-42. doi: 10.2146/ajhp110632. Am J Health Syst Pharm. 2013. PMID: 23413168 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon